Log in

Relevant bibliographies by topics / Rotavirus mucosal vaccines / Journal articles

To see the other types of publications on this topic, follow the link: Rotavirus mucosal vaccines.

Journal articles on the topic 'Rotavirus mucosal vaccines'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Rotavirus mucosal vaccines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Chen, Shing C., David H. Jones, Ellen F. Fynan, et al. "Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles." Journal of Virology 72, no. 7 (1998): 5757–61. http://dx.doi.org/10.1128/jvi.72.7.5757-5761.1998.

Full text

Abstract:

DNA vaccines are usually given by intramuscular injection or by gene gun delivery of DNA-coated particles into the epidermis. Induction of mucosal immunity by targeting DNA vaccines to mucosal surfaces may offer advantages, and an oral vaccine could be effective for controlling infections of the gut mucosa. In a murine model, we obtained protective immune responses after oral immunization with a rotavirus VP6 DNA vaccine encapsulated in poly(lactide-coglycolide) (PLG) microparticles. One dose of vaccine given to BALB/c mice elicited both rotavirus-specific serum antibodies and intestinal immun

APA, Harvard, Vancouver, ISO, and other styles

2

Montenegro, Catherine, Federico Perdomo-Celis, and Manuel A. Franco. "Update on Early-Life T Cells: Impact on Oral Rotavirus Vaccines." Viruses 16, no. 6 (2024): 818. http://dx.doi.org/10.3390/v16060818.

Full text

Abstract:

Rotavirus infection continues to be a significant public health problem in developing countries, despite the availability of several vaccines. The efficacy of oral rotavirus vaccines in young children may be affected by significant immunological differences between individuals in early life and adults. Therefore, understanding the dynamics of early-life systemic and mucosal immune responses and the factors that affect them is essential to improve the current rotavirus vaccines and develop the next generation of mucosal vaccines. This review focuses on the advances in T-cell development during

APA, Harvard, Vancouver, ISO, and other styles

3

Lee, Sangun, Boris R. Belitsky, James P. Brinker, et al. "Development of a Bacillus subtilis-Based Rotavirus Vaccine." Clinical and Vaccine Immunology 17, no. 11 (2010): 1647–55. http://dx.doi.org/10.1128/cvi.00135-10.

Full text

Abstract:

ABSTRACT Bacillus subtilis vaccine strains engineered to express either group A bovine or murine rotavirus VP6 were tested in adult mice for their ability to induce immune responses and provide protection against rotavirus challenge. Mice were inoculated intranasally with spores or vegetative cells of the recombinant strains of B. subtilis. To enhance mucosal immunity, whole cholera toxin (CT) or a mutant form (R192G) of Escherichia coli heat-labile toxin (mLT) were included as adjuvants. To evaluate vaccine efficacy, the immunized mice were challenged orally with EDIM EW murine rotavirus and

APA, Harvard, Vancouver, ISO, and other styles

4

Gilfillan, Darby, Allison C. Vilander, Meichen Pan, et al. "Lactobacillus acidophilus Expressing Murine Rotavirus VP8 and Mucosal Adjuvants Induce Virus-Specific Immune Responses." Vaccines 11, no. 12 (2023): 1774. http://dx.doi.org/10.3390/vaccines11121774.

Full text

Abstract:

Rotavirus diarrhea-associated illness remains a major cause of global death in children under five, attributable in part to discrepancies in vaccine performance between high- and low-middle-income countries. Next-generation probiotic vaccines could help bridge this efficacy gap. We developed a novel recombinant Lactobacillus acidophilus (rLA) vaccine expressing rotavirus antigens of the VP8* domain from the rotavirus EDIM VP4 capsid protein along with the adjuvants FimH and FliC. The upp-based counterselective gene-replacement system was used to chromosomally integrate FimH, VP8Pep (10 amino a

APA, Harvard, Vancouver, ISO, and other styles

5

Coste, Alix, Jean-Claude Sirard, Kari Johansen, Jean Cohen, and Jean-Pierre Kraehenbuhl. "Nasal Immunization of Mice with Virus-Like Particles Protects Offspring against Rotavirus Diarrhea." Journal of Virology 74, no. 19 (2000): 8966–71. http://dx.doi.org/10.1128/jvi.74.19.8966-8971.2000.

Full text

Abstract:

ABSTRACT Rotavirus is the major cause of diarrhea among young infants in both humans and animals. Immune protection of newborns by vaccination is difficult to achieve since there is not enough time to mount an immune response before exposure to the virus. We have designed a vaccination strategy mediating transfer of neutralizing antibodies from the mother to the offspring during pregnancy and/or lactation. Adult female mice were nasally immunized with virus-like particles (VLPs) made of viral proteins VP2 and 6 (VLP2/6) or VP 2, 6, and 7 (VLP2/6/7) derived from the RF rotavirus strain in the p

APA, Harvard, Vancouver, ISO, and other styles

6

Hu, Jingping, Jinyuan Wu, Han Cao, et al. "Effects of Rotavirus NSP4 on the Immune Response and Protection of Rotavirus-Norovirus Recombinant Subunit Vaccines in Different Immune Pathways." Vaccines 12, no. 9 (2024): 1025. http://dx.doi.org/10.3390/vaccines12091025.

Full text

Abstract:

Diarrheal disease continues to be a major cause of global morbidity and mortality among children under 5 years of age. To address the current issues associated with oral attenuated rotavirus vaccines, the study of parenteral rotavirus vaccines has promising prospects. In our previous study, we reported that rotavirus nonstructural protein 4 (NSP4) did not increase the IgG antibody titer of co-immune antigen but did have a protective effect against diarrhea via the intramuscular injection method. Here, we explored whether NSP4 can exert adjuvant effects on mucosal immune pathways. In this study

APA, Harvard, Vancouver, ISO, and other styles

7

Otero, Claire E., Stephanie N. Langel, Maria Blasi, and Sallie R. Permar. "Maternal antibody interference contributes to reduced rotavirus vaccine efficacy in developing countries." PLOS Pathogens 16, no. 11 (2020): e1009010. http://dx.doi.org/10.1371/journal.ppat.1009010.

Full text

Abstract:

Rotavirus (RV) vaccine efficacy is significantly reduced in lower- and middle-income countries (LMICs) compared to high-income countries. This review summarizes current research into the mechanisms behind this phenomenon, with a particular focus on the evidence that maternal antibody (matAb) interference is a contributing factor to this disparity. All RV vaccines currently in use are orally administered, live-attenuated virus vaccines that replicate in the infant gut, which leaves their efficacy potentially impacted by both placentally transferred immunoglobulin G (IgG) and mucosal IgA Abs con

APA, Harvard, Vancouver, ISO, and other styles

8

Wang, Jun, Songkang Qin, Kuanhao Li, Xin Yin, Dongbo Sun, and Jitao Chang. "Rotavirus Reverse Genetics Systems and Oral Vaccine Delivery Vectors for Mucosal Vaccination." Microorganisms 13, no. 7 (2025): 1579. https://doi.org/10.3390/microorganisms13071579.

Full text

Abstract:

Mucosal immunization represents a promising strategy for preventing enteric infections. Rotavirus (RV), a leading gastrointestinal pathogen distinguished by its remarkable stability and segmented double-stranded RNA genome, has been engineered into a versatile oral vaccine vector through advanced reverse genetics systems. The clinical efficacy of live-attenuated RV vaccines highlights their unique capacity to concurrently induce mucosal IgA responses and systemic neutralizing antibodies, positioning them as a multiple action vector for multiple immune protection. In this review, we summarize t

APA, Harvard, Vancouver, ISO, and other styles

9

Azevedo, Marli S. P., Ana Maria Gonzalez, Lijuan Yuan, et al. "An Oral versus Intranasal Prime/Boost Regimen Using Attenuated Human Rotavirus or VP2 and VP6 Virus-Like Particles with Immunostimulating Complexes Influences Protection and Antibody-Secreting Cell Responses to Rotavirus in a Neonatal Gnotobiotic Pig Model." Clinical and Vaccine Immunology 17, no. 3 (2010): 420–28. http://dx.doi.org/10.1128/cvi.00395-09.

Full text

Abstract:

ABSTRACT We determined the impact of mucosal prime/boost regimens and vaccine type (attenuated Wa human rotavirus [AttHRV] or nonreplicating Wa 2/6 rotavirus-like particles [VLP]) on protection and antibody-secreting cell (ASC) responses to HRV in a neonatal gnotobiotic pig disease model. Comparisons of delivery routes for AttHRV and evaluation of nonreplicating VLP vaccines are important as alternative vaccine approaches to overcome risks associated with live oral vaccines. Groups of neonatal gnotobiotic pigs were vaccinated using combinations of oral (PO) and intranasal (IN) inoculation rout

APA, Harvard, Vancouver, ISO, and other styles

10

MacDonald, Jaime, Michelle J. Groome, Janet Mans, and Nicola Page. "FUT2 Secretor Status Influences Susceptibility to VP4 Strain-Specific Rotavirus Infections in South African Children." Pathogens 9, no. 10 (2020): 795. http://dx.doi.org/10.3390/pathogens9100795.

Full text

Abstract:

Gastroenteritis is a preventable cause of morbidity and mortality worldwide. Rotavirus vaccination has significantly reduced the disease burden, but the sub-optimal vaccine efficacy observed in low-income regions needs improvement. Rotavirus VP4 ‘spike’ proteins interact with FUT2-defined, human histo-blood group antigens on mucosal surfaces, potentially influencing strain circulation and the efficacy of P[8]-based rotavirus vaccines. Secretor status was investigated in 500 children <5 years-old hospitalised with diarrhoea, including 250 previously genotyped rotavirus-positive cases (P[8] =

APA, Harvard, Vancouver, ISO, and other styles

11

Zainutdinov, S. S., G. F. Sivolobova, V. B. Loktev, and G. V. Kochneva. "Mucosal immunity and vaccines against viral infections." Problems of Virology 66, no. 6 (2022): 399–408. http://dx.doi.org/10.36233/0507-4088-82.

Full text

Abstract:

Mucosal immunity is realized through a structural and functional system called mucose-associated lymphoid tissue (MALT). MALT is subdivided into parts (clusters) depending on their anatomical location, but they all have a similar structure: mucus layer, epithelial tissue, lamina propria and lymphoid follicles. Plasma cells of MALT produce a unique type of immunoglobulins, IgA, which have the ability to polymerize. In mucosal immunization, the predominant form of IgA is a secretory dimer, sIgA, which is concentrated in large quantities in the mucosa. Mucosal IgA acts as a first line of defense

APA, Harvard, Vancouver, ISO, and other styles

12

O’Neal, Christine M., John D. Clements, Mary K. Estes, and Margaret E. Conner. "Rotavirus 2/6 Viruslike Particles Administered Intranasally with Cholera Toxin, Escherichia coli Heat-Labile Toxin (LT), and LT-R192G Induce Protection from Rotavirus Challenge." Journal of Virology 72, no. 4 (1998): 3390–93. http://dx.doi.org/10.1128/jvi.72.4.3390-3393.1998.

Full text

Abstract:

ABSTRACT We have shown that rotavirus 2/6 viruslike particles composed of proteins VP2 and VP6 (2/6-VLPs) administered to mice intranasally with cholera toxin (CT) induced protection from rotavirus challenge, as measured by virus shedding. Since it is unclear if CT will be approved for human use, we evaluated the adjuvanticity of Escherichia coli heat-labile toxin (LT) and LT-R192G. Mice were inoculated intranasally with 10 μg of 2/6-VLPs combined with CT, LT, or LT-R192G. All three adjuvants induced equivalent geometric mean titers of rotavirus-specific serum antibody and intestinal immunoglo

APA, Harvard, Vancouver, ISO, and other styles

13

Li, Zhipeng, Kuiqing Cui, Kongwei Huang, Fuhang Liu, Deshun Shi, and Qingyou Liu. "Self-assembling Rotavirus VP6 Nanoparticle Vaccines Expressed in Escherichia coli Elicit Systemic and Mucosal Responses in Mice." Protein & Peptide Letters 26, no. 12 (2019): 904–9. http://dx.doi.org/10.2174/0929866526666190820161328.

Full text

Abstract:

Background: Rotavirus is the most common cause of infectious diarrhea in infants and young children around the world. The inner capsid protein VP6 has been discussed as alternative vaccine as it can induce cross-protective immune responses against different RV strai. The use of ferritin nanoparticle may enhance the immunogenicity of the subunit vaccine. Objective: In this article, our motivation is to design and obtain a self-assemble rotavirus nanoparticle vaccine which can induce efficiency immune response. Methods: The VP6 protein was fused with ferritin and expressed in the Escherichia col

APA, Harvard, Vancouver, ISO, and other styles

14

Azevedo, Marli S. P., Lijuan Yuan, Cristiana Iosef, et al. "Magnitude of Serum and Intestinal Antibody Responses Induced by Sequential Replicating and Nonreplicating Rotavirus Vaccines in Gnotobiotic Pigs and Correlation with Protection." Clinical Diagnostic Laboratory Immunology 11, no. 1 (2004): 12–20. http://dx.doi.org/10.1128/cdli.11.1.12-20.2004.

Full text

Abstract:

ABSTRACT A sequential mucosal prime-boost vaccine regimen of oral attenuated (Att) human rotavirus (HRV) priming followed by intranasal (i.n.) boosting with rotavirus protein VP2 and VP6 rotavirus-like particles (2/6-VLPs) has previously been shown to be effective for induction of intestinal antibody-secreting cell (ASC) responses and protection in gnotobiotic pigs. Because serum or fecal antibody titers, but not intestinal ASC responses, can be used as potential markers of protective immunity in clinical vaccine trials, we determined the serum and intestinal antibody responses to this prime-b

APA, Harvard, Vancouver, ISO, and other styles

15

Parreno, Viviana, Muqun Bai, Fangning Liu, et al. "Probiotic as Adjuvant Significantly Improves Protection of the Lanzhou Trivalent Rotavirus Vaccine against Heterologous Challenge in a Gnotobiotic Pig Model of Human Rotavirus Infection and Disease." Vaccines 10, no. 9 (2022): 1529. http://dx.doi.org/10.3390/vaccines10091529.

Full text

Abstract:

This preclinical study in the gnotobiotic (Gn) pig model of human rotavirus (HRV) infection and disease evaluates the effect of probiotic Lactobacillus rhamnosus GG (LGG) as a mucosal adjuvant on the immunogenicity and cross-protective efficacy of the Lanzhou live oral trivalent (G2, G3, G4) vaccine (TLV, aka LLR3). Gn pigs were immunized with three doses of TLV with or without concurrent administration of nine doses of LGG around the time of the first dose of the TLV vaccination, and were challenged orally with the virulent heterotypic Wa G1P[8] HRV. Three doses of TLV were highly immunogenic

APA, Harvard, Vancouver, ISO, and other styles

16

Norton, Elizabeth B. "New strategies for an old problem - Oral vaccines research." Open Access Government 45, no. 1 (2025): 36–37. https://doi.org/10.56367/oag-045-11805.

Full text

Abstract:

New strategies for an old problem - Oral vaccines research Despite their advantages, oral vaccines encounter several challenges. Professor Elizabeth Norton from Tulane University discusses how her team is addressing these issues and their research on developing and testing dmLT and saponin combination adjuvants. The gut is home to a remarkable concentration of the body’s immune cells, particularly antibody-secreting plasma cells. It serves as a critical site for interactions with microbes, exposure to pathogens, and maintaining overall health. Globally, several human vaccines leverage oral del

APA, Harvard, Vancouver, ISO, and other styles

17

Johansen, Finn-Eirik, Espen S. Baekkevold, Hege S. Carlsen, Inger Nina Farstad, Dulce Soler, and Per Brandtzaeg. "Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils." Blood 106, no. 2 (2005): 593–600. http://dx.doi.org/10.1182/blood-2004-12-4630.

Full text

Abstract:

Abstract Ethical constraints restrict direct tracking of immune-cell migration throughout the human body in vivo. We, therefore, used deletion of the immunoglobulin M (IgM) heavy-chain constant-gene (Cμ) segment as a marker to provide a dispersal signature of an effector B-cell subset (IgD+IgM-CD38+) induced selectively in human tonsils. By DNA analysis, the Cμ deletion identified dissemination of such blasts and their plasma-cell progeny to peripheral blood, lymph nodes, and bone marrow, as well as to mucosae and glands of the upper airways. Also the endocervix was often positive, while the s

APA, Harvard, Vancouver, ISO, and other styles

18

Yuan, Lijuan, Annelise Geyer, Douglas C. Hodgins, et al. "Intranasal Administration of 2/6-Rotavirus-Like Particles with Mutant Escherichia coli Heat-Labile Toxin (LT-R192G) Induces Antibody-Secreting Cell Responses but Not Protective Immunity in Gnotobiotic Pigs." Journal of Virology 74, no. 19 (2000): 8843–53. http://dx.doi.org/10.1128/jvi.74.19.8843-8853.2000.

Full text

Abstract:

ABSTRACT We investigated the immunogenicity of recombinant double-layered rotavirus-like particle (2/6-VLPs) vaccines derived from simian SA11 or human (VP6) Wa and bovine RF (VP2) rotavirus strains. The 2/6-VLPs were administered to gnotobiotic pigs intranasally (i.n.) with a mutantEscherichia coli heat-labile toxin, LT-R192G (mLT), as mucosal adjuvant. Pigs were challenged with virulent Wa (P1A[8],G1) human rotavirus at postinoculation day (PID) 21 (two-dose VLP regimen) or 28 (three-dose VLP regimen). In vivo antigen-activated antibody-secreting cells (ASC) (effector B cells) and in vitro a

APA, Harvard, Vancouver, ISO, and other styles

19

Buckner, Diana, Suzanne Wilson, Sandra Kurk, Michele Hardy, Nicole Miessner, and Mark A. Jutila. "Use of Early Passage Fetal Intestinal Epithelial Cells in Semi-High-Throughput Screening Assays: An Approach to Identify New Innate Immune System Adjuvants." Journal of Biomolecular Screening 11, no. 6 (2006): 664–71. http://dx.doi.org/10.1177/1087057106289876.

Full text

Abstract:

Innate immune system stimulants (innate adjuvants) offer complementary approaches to vaccines and antimicrobial compounds to increase host resistance to infection. The authors established fetal bovine intestinal epithelial cell (BIEC) cultures to screen natural product and synthetic compound libraries for novel mucosal adjuvants. They showed that BIECs from fetal intestine maintained an in vivo phenotype as reflected in cytokeratin expression, expression of antigens restricted to intestinal enterocytes, and induced interleukin-8 (IL-8) production. BIECs could be infected by and support replica

APA, Harvard, Vancouver, ISO, and other styles

20

Sharma, Sumit, and Johan Nordgren. "Effect of Infant and Maternal Secretor Status on Rotavirus Vaccine Take—An Overview." Viruses 13, no. 6 (2021): 1144. http://dx.doi.org/10.3390/v13061144.

Full text

Abstract:

Histo-blood group antigens, which are present on gut epithelial surfaces, function as receptors or attachment factors and mediate susceptibility to rotavirus infection. The major determinant for susceptibility is a functional FUT2 enzyme which mediates the presence of α-1,2 fucosylated blood group antigens in mucosa and secretions, yielding the secretor-positive phenotype. Secretors are more susceptible to infection with predominant rotavirus genotypes, as well as to the commonly used live rotavirus vaccines. Difference in susceptibility to the vaccines is one proposed factor for the varying d

APA, Harvard, Vancouver, ISO, and other styles

21

Yuan, Lijuan, Cristiana Iosef, Marli S. P. Azevedo, et al. "Protective Immunity and Antibody-Secreting Cell Responses Elicited by Combined Oral Attenuated Wa Human Rotavirus and Intranasal Wa 2/6-VLPs with Mutant Escherichia coli Heat-Labile Toxin in Gnotobiotic Pigs." Journal of Virology 75, no. 19 (2001): 9229–38. http://dx.doi.org/10.1128/jvi.75.19.9229-9238.2001.

Full text

Abstract:

ABSTRACT Two combined rotavirus vaccination regimens were evaluated in a gnotobiotic pig model of rotavirus infection and disease and were compared to previously tested rotavirus vaccination regimens. The first (AttHRV/VLP2×) involved oral inoculation with one dose of attenuated (Att) Wa human rotavirus (HRV), followed by two intranasal (i.n.) doses of a rotavirus-like particle (2/6-VLPs) vaccine derived from Wa (VP6) and bovine RF (VP2) rotavirus strains. The 2/6-VLPs were coadministered with a mutant Escherichia coli heat-labile toxin, LT-R192G (mLT) adjuvant. For the second regimen (VLP2×/A

APA, Harvard, Vancouver, ISO, and other styles

22

Li, Wanqiang, Jie Feng, Jiajun Li, et al. "Surface Display of Antigen Protein VP8* of Porcine Rotavirus on Bacillus Subtilis Spores Using CotB as a Fusion Partner." Molecules 24, no. 20 (2019): 3793. http://dx.doi.org/10.3390/molecules24203793.

Full text

Abstract:

Porcine rotavirus is a major cause of acute viral gastroenteritis in suckling piglets, and vaccination is considered to be an effective measure to control these infections. The development of a live mucosal vaccine using Bacillus subtilis spores as an antigen delivery vehicle is a convenient and attractive vaccination strategy against porcine rotavirus. In this study, a shuttle vector was constructed for the spore surface display of the spike protein VP8* from porcine rotavirus (the genotype was G5P[7]). A successful display of the CotB-VP8* fusion protein on the spore surface was confirmed by

APA, Harvard, Vancouver, ISO, and other styles

23

Yang, Xingdong, Ke Wen, Christine Tin, et al. "Dietary Rice Bran Protects against Rotavirus Diarrhea and Promotes Th1-Type Immune Responses to Human Rotavirus Vaccine in Gnotobiotic Pigs." Clinical and Vaccine Immunology 21, no. 10 (2014): 1396–403. http://dx.doi.org/10.1128/cvi.00210-14.

Full text

Abstract:

ABSTRACTRice bran (RB) contains a distinct stoichiometry of phytochemicals that can promote gut mucosal immune responses against enteric pathogens. The effects of RB on rotavirus diarrhea and immunogenicity of an attenuated human rotavirus (HRV) vaccine were evaluated in gnotobiotic pigs. The four treatment groups studied were RB plus vaccine, vaccine only, RB only, and mock control. Pigs in the RB groups were fed the amount of RB that replaced 10% of the pigs' total daily calorie intake from milk starting from 5 days of age until they were euthanized. Pigs in the vaccine groups were orally in

APA, Harvard, Vancouver, ISO, and other styles

24

Ciarlet, Max, Sue E. Crawford, Christopher Barone, et al. "Subunit Rotavirus Vaccine Administered Parenterally to Rabbits Induces Active Protective Immunity." Journal of Virology 72, no. 11 (1998): 9233–46. http://dx.doi.org/10.1128/jvi.72.11.9233-9246.1998.

Full text

Abstract:

ABSTRACT Virus-like particles (VLPs) are being evaluated as a candidate rotavirus vaccine. The immunogenicity and protective efficacy of different formulations of VLPs administered parenterally to rabbits were tested. Two doses of VLPs (2/6-, G3 2/6/7-, or P[2], G3 2/4/6/7-VLPs) or SA11 simian rotavirus in Freund’s adjuvants, QS-21 (saponin adjuvant), or aluminum phosphate (AlP) were administered. Serological and mucosal immune responses were evaluated in all vaccinated and control rabbits before and after oral challenge with 103 50% infective doses of live P[14], G3 ALA lapine rotavirus. All

APA, Harvard, Vancouver, ISO, and other styles

25

LOSONSKY, GENEVIEVE A., MARGARET B. RENNELS, Y. U. LIM, GAIL KRALL, ALBERT Z. KAPIKIAN, and MYRON M. LEVINE. "Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006." Pediatric Infectious Disease Journal 7, no. 6 (1988): 388–92. http://dx.doi.org/10.1097/00006454-198806000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Li, Yi-jing, Guang-peng Ma, Gui-wei Li, et al. "Oral Vaccination with the Porcine Rotavirus VP4 Outer Capsid Protein Expressed byLactococcus lactisInduces Specific Antibody Production." Journal of Biomedicine and Biotechnology 2010 (2010): 1–9. http://dx.doi.org/10.1155/2010/708460.

Full text

Abstract:

The objective of this study to design a delivery system resistant to the gastrointestinal environment for oral vaccine against porcine rotavirus.Lactococcus lactisNZ9000 was transformed with segments ofvP4of the porcine rotavirus inserted into the pNZ8112 surface-expression vector, and a recombinantL. lactisexpressing VP4 protein was constructed. An approximately 27 kDa VP4 protein was confirmed by SDS-PAGE , Western blot and immunostaining analysis. BALB/c mice were immunized orally with VP4-expression recombinantL. lactisand cellular, mucosal and systemic humoral immune responses were examin

APA, Harvard, Vancouver, ISO, and other styles

27

Lappalainen, Suvi, Ana Ruth Pastor, Maria Malm, et al. "Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine." Archives of Virology 160, no. 8 (2015): 2075–78. http://dx.doi.org/10.1007/s00705-015-2461-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Parez, Nathalie, Cynthia Fourgeux, Ali Mohamed, et al. "Rectal Immunization with Rotavirus Virus-Like Particles Induces Systemic and Mucosal Humoral Immune Responses and Protects Mice against Rotavirus Infection." Journal of Virology 80, no. 4 (2006): 1752–61. http://dx.doi.org/10.1128/jvi.80.4.1752-1761.2006.

Full text

Abstract:

ABSTRACT To evaluate whether the rectal route of immunization may be used to provide appropriate protection against enteric pathogens such as rotaviruses (RV), we studied the antibody response and the protection induced by rectal immunization of mice with RV virus-like particles (VLP). For this purpose, 6-week-old BALBc mice were rectally immunized twice with RV 8-2/6/7-VLP derived from the bovine RV RF81 strain either alone or combined with various adjuvants including four toxins [cholera toxin (CT) and three attenuated Escherichia coli-derived heat-labile toxins (LTs), LT(R192G), LT(R72), an

APA, Harvard, Vancouver, ISO, and other styles

29

Scarmozzino, Rocco, Giovanna Zanoni, Alessandra Arcolaci, and Rachele Ciccocioppo. "Vaccine Efficacy and Safety in Patients with Celiac Disease." Vaccines 12, no. 12 (2024): 1328. http://dx.doi.org/10.3390/vaccines12121328.

Full text

Abstract:

Celiac disease (CD) is an autoimmune disorder caused by gluten intake in genetically predisposed individuals. This article provides an overview of the available data on the risks of infectious diseases and the mechanisms involved in CD, including a detailed analysis of vaccine efficacy, immunogenicity, and safety. The published articles were retrieved from the PubMed database using the terms “celiac disease”, “efficacy”, “hyposplenism”, “immune response”, “infections”, “immunization”, “immunogenicity”, “safety”, “vaccination”, and “vaccine”. CD can be associated with several autoimmune disease

APA, Harvard, Vancouver, ISO, and other styles

30

Andreeva, Alfia, Oksana Nikolaeva, Oleg Altynbekov, Chulpan Galieva, and Kseniia Ilina. "Influence of interferon-based drugs on immunological indices in specific prevention." February-2020 13, no. 2 (2020): 238–44. http://dx.doi.org/10.14202/vetworld.2020.238-244.

Full text

Abstract:

Aim: The research aimed to study the effect of interferon (IFN)-based drugs on the behavior of immunological parameters in calves during the specific prevention of associative infections. Materials and Methods: The object of research was 45 black motley cows and their calves from birth to 2 months of life. Serum and colostrum samples were screened for antibodies against Rotavirus, diarrhea, and coronavirus using serological methods. The testing was performed before vaccination, 40 days before calving, 20 days before calving, and before calving. Colostrum samples were taken during the first mil

APA, Harvard, Vancouver, ISO, and other styles

31

McNeal, Monica M., John L. VanCott, Anthony H. C. Choi, et al. "CD4 T Cells Are the Only Lymphocytes Needed To Protect Mice against Rotavirus Shedding after Intranasal Immunization with a Chimeric VP6 Protein and the Adjuvant LT(R192G)." Journal of Virology 76, no. 2 (2002): 560–68. http://dx.doi.org/10.1128/jvi.76.2.560-568.2002.

Full text

Abstract:

ABSTRACT Intranasal immunization of mice with a chimeric VP6 protein and the mucosal adjuvant Escherichia coli heat labile toxin LT(R192G) induces nearly complete protection against murine rotavirus (strain EDIM [epizootic diarrhea of infant mice virus]) shedding for at least 1 year. The aim of this study was to identify the protective lymphocytes elicited by this new vaccine candidate. Immunization of mouse strains lacking one or more lymphocyte populations revealed that protection was dependent on αβ T cells but mice lacking γδ T cells and B cells remained fully protected. Furthermore, deple

APA, Harvard, Vancouver, ISO, and other styles

32

Zhang, Hailin, Haiyuan Zhao, Yuliang Zhao, et al. "Auxotrophic Lactobacillus Expressing Porcine Rotavirus VP4 Constructed Using CRISPR-Cas9D10A System Induces Effective Immunity in Mice." Vaccines 10, no. 9 (2022): 1510. http://dx.doi.org/10.3390/vaccines10091510.

Full text

Abstract:

Porcine rotavirus (PoRV) mainly causes acute diarrhea in piglets under eight weeks of age and has potentially high morbidity and mortality rates. As vaccine carriers for oral immunization, lactic acid bacteria (LAB) are an ideal strategy for blocking PoRV infections. However, the difficulty in knocking out specific genes, inserting foreign genes, and the residues of antibiotic selection markers are major challenges for the oral vaccination of LAB. In this study, the target gene, alanine racemase (alr), in the genome of Lactobacillus casei strain W56 (L. casei W56) was knocked out to construct

APA, Harvard, Vancouver, ISO, and other styles

33

Yuan, Lijuan, Marli S. P. Azevedo, Ana M. Gonzalez, et al. "Mucosal and systemic antibody responses and protection induced by a prime/boost rotavirus-DNA vaccine in a gnotobiotic pig model." Vaccine 23, no. 30 (2005): 3925–36. http://dx.doi.org/10.1016/j.vaccine.2005.03.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kandasamy, Sukumar, Kuldeep S. Chattha, Anastasia N. Vlasova, Gireesh Rajashekara, and Linda J. Saif. "Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model." Gut Microbes 5, no. 5 (2014): 639–51. http://dx.doi.org/10.4161/19490976.2014.969972.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Lee, Benjamin, Md Abdul Kader, E. Ross Colgate, et al. "Oral rotavirus vaccine shedding as a marker of mucosal immunity." Scientific Reports 11, no. 1 (2021). http://dx.doi.org/10.1038/s41598-021-01288-1.

Full text

Abstract:

AbstractGroup A rotaviruses (RVA) remain a leading cause of pediatric diarrhea worldwide, in part due to underperformance of currently approved live-attenuated, oral vaccines in low-and-middle income countries. Improved immune correlates of protection (CoP) for existing oral vaccines and novel strategies to evaluate the performance of next-generation vaccines are needed. Use of oral vaccines as challenge agents in controlled human infection models is a potential approach to CoP discovery that remains underexplored. In a live-attenuated, oral rotavirus vaccine (Rotarix, GlaxoSmithKline) efficac

APA, Harvard, Vancouver, ISO, and other styles

36

Ward, Richard L. "Rotavirus vaccines: how they work or don't work." Expert Reviews in Molecular Medicine 10 (February 2008). http://dx.doi.org/10.1017/s1462399408000574.

Full text

Abstract:

In 2004 and 2006, two new rotavirus vaccines – Rotarix™and RotaTeq™– were licensed worldwide. Both are live virus vaccines and are composed of either a monovalent attenuated human rotavirus or five bovine–human reassortant rotaviruses, respectively. Studies in humans and animals have reported correlations between rotavirus antibody levels and protection, the most consistent of which has been with rotavirus IgA. Cellular immunity was also found to have a role in protection after live rotavirus immunisation, particularly in mice. However, the primary importance of CD8+T cells may be in resolutio

APA, Harvard, Vancouver, ISO, and other styles

37

Burke, Rachel M., Sasirekha Ramani, Julia Lynch, et al. "Geographic disparities impacting oral vaccine performance: Observations and future directions." Clinical and Experimental Immunology, January 8, 2025. https://doi.org/10.1093/cei/uxae124.

Full text

Abstract:

Abstract Oral vaccines have several advantages compared with parenteral administration: they can be relatively cheap to produce in high quantities, easier to administer, and induce intestinal mucosal immunity that can protect against infection. These characteristics have led to successful use of oral vaccines against rotavirus, polio, and cholera. Unfortunately, oral vaccines for all three diseases have demonstrated lower performance in the highest-burden settings where they are most needed. Rotavirus vaccines are estimated to have &gt;85% effectiveness against hospitalization in children

APA, Harvard, Vancouver, ISO, and other styles

38

Keerthana, N. A., Kanthesh M. Basalingappa, T. S. Gopenath, et al. "Edible vaccines." International journal of health sciences, June 1, 2022. http://dx.doi.org/10.53730/ijhs.v6ns3.8248.

Full text

Abstract:

Infectious diseases cause more than one million deaths every year. Fifty percent of these diseases are caused by bacteria that infect the mucosal membrane of the mammalian host. Vaccines are recognized worldwide as one of the most effective resources against infectious diseases. It is a biological product that can improve the immune response to specific diseases. Edible vaccines are referred to the use of edible parts of the genetically modified plants. It effects on the lining of the gastrointestinal tract allows the activation of systemic immunity and mucosal immunity (GIT). Edible vaccines

APA, Harvard, Vancouver, ISO, and other styles

39

Kiliccalan, Ibrahim. "Is the Rotavirus Vaccine Really Associated with a Decreased Risk of Developing Celiac and Other Autoimmune Diseases?" Rambam Maimonides Medical Journal, August 25, 2021. http://dx.doi.org/10.5041/rmmj.10450.

Full text

Abstract:

This review examines the risk of developing celiac disease (CD) and other autoimmune diseases in individuals receiving the rotavirus (RV) vaccine compared to the normal population. Celiac disease is a malabsorptive, chronic, immune-mediated enteropathy involving the small intestine. The pathogenesis of CD is multifactorial, and mucosal immunity plays an important role in its development. Low mucosal IgA levels significantly increase the risk of developing the disease. Rotavirus is an infectious agent that causes diarrhea, particularly in children aged 0–24 months, and is frequently involved in

APA, Harvard, Vancouver, ISO, and other styles

40

Aurelio Palazzi Sáfadi, Marco. "Vaccine Types." VacciTUTOR, November 8, 2021. http://dx.doi.org/10.33442/vt202106.

Full text

Abstract:

Vaccines are biological preparations, often made from attenuated or killed forms of microorganisms or fractions thereof. They work by stimulating the immune system to produce antibodies and cells directed against a particular organism, mimicking "natural infection". Based on their biological and chemical characteristics, vaccines can be categorized into two basic types, "Live-attenuated" (bacterial or viral) vaccines and "inactivated" or "non-live" vaccines. Examples of live-attenuated vaccines include: measles-, mumps-, and rubella-, varicella-, yellow fever-, oral polio- (OPV), rotavirus-, (

APA, Harvard, Vancouver, ISO, and other styles

41

Kawagishi, Takahiro, Liliana Sánchez-Tacuba, Ningguo Feng, et al. "Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses." Proceedings of the National Academy of Sciences 120, no. 9 (2023). http://dx.doi.org/10.1073/pnas.2214421120.

Full text

Abstract:

Rotaviruses (RVs) preferentially replicate in the small intestine and frequently cause severe diarrheal disease, and the following enteric infection generally induces variable levels of protective systemic and mucosal immune responses in humans and other animals. Rhesus rotavirus (RRV) is a simian RV that was previously used as a human RV vaccine and has been extensively studied in mice. Although RRV replicates poorly in the suckling mouse intestine, infection induces a robust and protective antibody response. The recent availability of plasmid only-based RV reverse genetics systems has enable

APA, Harvard, Vancouver, ISO, and other styles

42

Yang, Heng, Xiangqi Fan, Xiangbing Mao, et al. "The protective role of prebiotics and probiotics on diarrhea and gut damage in the rotavirus-infected piglets." Journal of Animal Science and Biotechnology 15, no. 1 (2024). http://dx.doi.org/10.1186/s40104-024-01018-3.

Full text

Abstract:

AbstractRotavirus is one of the pathogenic causes that induce diarrhea in young animals, especially piglets, worldwide. However, nowadays, there is no specific drug available to treat the disease, and the related vaccines have no obvious efficiency in some countries. Via analyzing the pathogenesis of rotavirus, it inducing diarrhea is mainly due to disturb enteric nervous system, destroy gut mucosal integrity, induce intracellular electrolyte imbalance, and impair gut microbiota and immunity. Many studies have already proved that prebiotics and probiotics can mitigate the damage and diarrhea i

APA, Harvard, Vancouver, ISO, and other styles

43

Cui, Tingting, Jun Xiong, Yongzhi Wang, et al. "Construction of an artificial recombinant bicistronic plasmid DNA vaccine against porcine rotavirus." Onderstepoort J Vet Res 80, no. 1 (2013). http://dx.doi.org/10.4102/ojvr.v80i1.498.

Full text

Abstract:

The attenuated Salmonella typhimurium χ4550 strain was used to harbour a reconstructed bicistronic DNA vaccine against porcine rotavirus, which carried the rotavirus nonstructural protein 4 (NSP4) and VP7 genes simultaneously. Using a balanced lethal system, the kanamycin resistance gene of expressing eukaryotic plasmids pVAX1 and pVAXD were replaced by the aspartate β-semialdehyde dehydrogenase (asd) gene. The NSP4 cleavage product (259–525) of rotavirus OSU strain and VP7 full-length genes were amplified by reverse transcription polymerase chain reaction and then inserted into the eukaryotic

APA, Harvard, Vancouver, ISO, and other styles

44

Philip, Asha A., Sannoong Hu, Jin Dai, and John T. Patton. "Recombinant rotavirus expressing the glycosylated S1 protein of SARS-CoV-2." Journal of General Virology 104, no. 10 (2023). http://dx.doi.org/10.1099/jgv.0.001899.

Full text

Abstract:

Reverse genetic systems have been used to introduce heterologous sequences into the rotavirus segmented double-stranded (ds)RNA genome, enabling the generation of recombinant viruses that express foreign proteins and possibly serve as vaccine vectors. Notably, insertion of SARS-CoV-2 sequences into the segment seven (NSP3) RNA of simian SA11 rotavirus was previously shown to result in the production of recombinant viruses that efficiently expressed the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the S1 region of the SARS-CoV-2 spike protein. However, efforts to generate a

APA, Harvard, Vancouver, ISO, and other styles

45

Guo, Tiantian, Chong Gao, Jianhui Hao, et al. "Strategy of Developing Oral Vaccine Candidates Against Co-infection of Porcine Diarrhea Viruses Based on a Lactobacillus Delivery System." Frontiers in Microbiology 13 (April 4, 2022). http://dx.doi.org/10.3389/fmicb.2022.872550.

Full text

Abstract:

The number of co-infections with multiple porcine diarrhea viruses has increased in recent years. Inducing mucosal immunity through oral immunization is an effective approach for controlling these pathogens. To generate a multi-pathogen vaccine against viral co-infection, we employed the Lactobacillus vector platform, which was previously used to generate potent candidate vaccines against various diseases. Two strategies were used to test the protective efficiency of recombinant Lactobacillus against multiple diarrhea viruses. First, we used a mixture of recombinant Lactobacillus separately ex

APA, Harvard, Vancouver, ISO, and other styles

46

Langridge, William, Oludare Odumosu, Somen Nandi, Raymond Rodriguez, Marino DeLeon, and Zaida Cordero-MacIntyre. "Mucosal Vaccination against Enteric Pathogens in the Developing World." March 25, 2012. https://doi.org/10.5281/zenodo.7809.

Full text

Abstract:

Of the approximately 9 million children under the age of 5 yr that die annually in developing nations, about 5.1 million will die from preventable infectious diseases. This disastrous human and economic loss is caused in large part by three types of acute diarrhea and attendant respiratory tract infections that are responsible for approximately 2.6 million of these deaths. Thus, enteric pathogens remain a major factor contributing to persistent poverty and poor health in developing nations. Novel mucosal vaccination strategies are emerging that can protect epithelial surfaces and therefore pro

APA, Harvard, Vancouver, ISO, and other styles

47

Kawamura, Yoshiki, Satoshi Komoto, Saori Fukuda, et al. "2136. Development of Recombinant Rotavirus Vaccine Carrying Herpes Simplex Virus 2 Gene Based on Reverse Genetics Technology." Open Forum Infectious Diseases 9, Supplement_2 (2022). http://dx.doi.org/10.1093/ofid/ofac492.1756.

Full text

Abstract:

Abstract Background Herpes simplex virus type 2 (HSV-2) can cause genital herpes, which reduces the patient's QOL associated with pain. In addition, genital herpes can increase the risk of human immunodeficiency virus infection. Vaccine development has been attempted for many years, but it has not yet been put into practical use. Meanwhile, rotavirus (RV) is one of the major viral causes of severe gastroenteritis in infants and young children worldwide. Currently, two live attenuated vaccines are widely used to prevent severe RV infection in children. We have developed entirely plasmid-based r

APA, Harvard, Vancouver, ISO, and other styles

48

Riller, Quentin, Muriel Schmutz, Jacques Fourgeaud, Alain Fischer, and Bénédicte Neven. "Protective role of antibodies in enteric virus infections: Lessons from primary and secondary immune deficiencies." Immunological Reviews, September 28, 2024. http://dx.doi.org/10.1111/imr.13402.

Full text

Abstract:

SummaryEnteric viruses are the main cause of acute gastroenteritis worldwide with a significant morbidity and mortality, especially among children and aged adults. Some enteric viruses also cause disseminated infections and severe neurological manifestations such as poliomyelitis. Protective immunity against these viruses is not well understood in humans, with most knowledge coming from animal models, although the development of poliovirus and rotavirus vaccines has extended our knowledge. In a classical view, innate immunity involves the recognition of foreign DNA or RNA by pathogen recogniti

APA, Harvard, Vancouver, ISO, and other styles

49

Resch, Theresa K., Yuhuan Wang, Sung-Sil Moon, et al. "Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice." Scientific Reports 8, no. 1 (2018). http://dx.doi.org/10.1038/s41598-017-18973-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Williams, Frank B., Abdul Kader, E. Ross Colgate, et al. "Maternal Secretor Status Affects Oral Rotavirus Vaccine Response in Breastfed Infants in Bangladesh." Journal of Infectious Diseases, March 11, 2020. http://dx.doi.org/10.1093/infdis/jiaa101.

Full text

Abstract:

Abstract Secretor status controls mucosal histo–blood group antigen expression and is associated with susceptibility to rotavirus (RV) diarrhea, with nonsecretors less susceptible to symptomatic infection. The role of breast milk secretor status on oral live-attenuated RV vaccine response in breastfed infants has not been explored. In a monovalent G1P[8] RV vaccine (Rotarix) trial in Bangladesh, RV-specific plasma immunoglobulin A antibody seroconversion rates were higher among infants of maternal nonsecretors (39%) than infants of maternal secretors (23%; P = .001). Maternal status remained a

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!